Given that LCC is relatively rare among NSCLCs, with no targetable genetic abnormality or effective chemotherapy, and a higher expression of PD‐L1 compared to other NSCLCs, we believe that ICIs may be an important treatment option for LCC. This evidence concerns the gene CD274 and leukoencephalopathy with calcifications and cysts.